Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy.
J Diabetes Res
; 2015: 962383, 2015.
Article
en En
| MEDLINE
| ID: mdl-26421309
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD). The development and progression of DN might involve multiple factors. Connective tissue growth factor (CCN2, originally known as CTGF) is the one which plays a pivotal role. Therefore, increasing attention is being paid to CCN2 as a potential therapeutic target for DN. Up to date, there are also many drugs or agents which have been shown for their protective effects against DN via different mechanisms. In this review, we only focus on the potential renoprotective therapeutic agents which can specifically abolish CCN2 expression or nonspecifically inhibit CCN2 expression for retarding the development and progression of DN.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Diabetes Mellitus
/
Nefropatías Diabéticas
/
Factor de Crecimiento del Tejido Conjuntivo
/
Riñón
Límite:
Animals
/
Humans
Idioma:
En
Revista:
J Diabetes Res
Año:
2015
Tipo del documento:
Article
País de afiliación:
China
Pais de publicación:
Reino Unido